Larimar Therapeutics, Inc. (LRMR)

NGM – Real Time Price. Currency in USD

4.13

+0.04 (0.98%)

At close: May 12, 2026, 4:00 PM EDT

4.09

-0.04 (-0.97%)

Pre-market: May 13, 2026, 9:08 AM EDT

19.03.2026

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $107.6 million in net proceeds from the recently completed February 2026 public offering.

08.03.2026

2 Breakout Stocks to Buy Immediately

Tom Yeung here with your Sunday Digest . In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.

06.03.2026

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.

04.03.2026

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL.

26.02.2026

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about February 27, 2026, subject to the satisfaction of customary closing conditions.

25.02.2026

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.

25.02.2026

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook.

Videos

No Data

There is no data to display

Press releases

19.03.2026

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

26.02.2026

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

25.02.2026

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.

24.02.2026

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission seeking accelerated approval Topline open label study data to support BLA submission expected in Q2 2026 Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved BALA CYNWYD, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to nomlabofusp, a frataxin (FXN) protein replacement therapy with disease modifying potential, for the treatment of adults and children with Friedreich's ataxia (FA).

Larimar Therapeutics, Inc. (LRMR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

2 Breakout Stocks to Buy Immediately

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Videos

No Data

Press releases

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

2 Breakout Stocks to Buy Immediately

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Videos

No Data

Press releases

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Search stocks

Larimar Therapeutics, Inc. (LRMR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

2 Breakout Stocks to Buy Immediately

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Videos

No Data

Press releases

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

2 Breakout Stocks to Buy Immediately

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Videos

No Data

Press releases

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026